HomeGNMSF • OTCMKTS
add
Genmab A/S
Previous close
$207.62
Day range
$210.30 - $212.48
Year range
$186.61 - $323.02
Market cap
14.01B USD
Avg Volume
5.08K
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
Financials
Income Statement
Revenue
Net income
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 6.44B | 35.34% |
Operating expense | 3.84B | 33.14% |
Net income | 3.84B | 446.94% |
Net profit margin | 59.70 | 304.20% |
Earnings per share | 0.84 | -91.36% |
EBITDA | 2.36B | 31.71% |
Effective tax rate | -6.75% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 21.10B | -25.00% |
Total assets | 45.81B | 29.82% |
Total liabilities | 9.11B | 147.73% |
Total equity | 36.70B | — |
Shares outstanding | 63.54M | — |
Price to book | 0.36 | — |
Return on assets | 13.26% | — |
Return on capital | 16.05% | — |
Cash Flow
Net change in cash
| (DKK) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 3.84B | 446.94% |
Cash from operations | 2.71B | 62.20% |
Cash from investing | 82.00M | 118.55% |
Cash from financing | 3.00M | 113.64% |
Net change in cash | 3.52B | 491.92% |
Free cash flow | 1.83B | 41.20% |
About
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
Founded
1999
Website
Employees
2,682
